Macrophage Proteoglycans in Atherosclerosis

Informations projet

ATHEROGAG

N° de convention de subvention: 273994

Projet clôturé

Date de début 1 Juillet 2011

Date de fin 18 Juin 2015

Financé au titre de

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Coût total € 179 390,40

Contribution de l’UE € 179 390,40

Coordonné par

KATHOLIEKE UNIVERSITEIT LEUVEN
Belgique

Objectif

Cardiovascular diseases (CVD) are the leading cause of death in Western societies. CVD-related deaths are primarily caused by complications of atherosclerosis, a disease initiated via focal infiltration and retention of lipoproteins in the subendothelial matrix of arteries due to a combination of aggregation and interaction with proteoglycans produced by the arteries. Little is known about the in vivo contribution of macrophage-derived and -associated proteoglycans during atherosclerosis development and progression. Considering this dearth of knowledge we will address two objectives: First, we want to determine the in vivo impact of reduced sulfation of macrophage proteoglycans on atherosclerosis using conditional mouse models lacking macrophage-specific Ndst1 functionality on an LDLR-deficient background. Atherosclerotic lesion quantity and quality will be analyzed in conjunction with macrophage lesion infiltration and lesion apoptosis and efferocytosis. Secondly, we want to evaluate the importance of proteoglycans for macrophage foam cell conversion, another key event in atherogenesis. Using macrophage cell cultures from wild-type or mutant mice we want to determine the importance of biosynthetic genes involved and the array of proteoglycans expressed before and after conversion. In addition the cells will be used to identify a specific proteoglycan important for conversion which will be consequently evaluated for its impact on atherosclerosis in vivo. During his mobility, the applicant will receive didactic (glycobiology, management, intellectual property, grants) and hands-on (MS, macrophage cultures, qPCR, shRNA, flow assay) training as well as network opportunities which will be implemented in the European return institution. Altogether, the generated data should add to our understanding of macrophage proteoglycans and their importance for CVD and provide the opportunity for identifying drug targets and for transfer of US collaborations and know-how to the EU

Champ scientifique (EuroSciVoc)

CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN. Voir: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

• sciences médicales et de la santé › médecine clinique › cardiologie › maladies cardiovasculaires › artériosclérose

Vous devez vous identifier ou vous inscrire pour utiliser cette fonction

Programme(s)

• FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Thème(s)

• FP7-PEOPLE-2010-IOF - Marie Curie Action: "International Outgoing Fellowships for Career Development"

Appel à propositions

FP7-PEOPLE-2010-IOF
Voir d’autres projets de cet appel

Régime de financement

MC-IOF -

Coordinateur

KATHOLIEKE UNIVERSITEIT LEUVEN

• Contribution de l’UE: € 179 390,40
• Adresse: OUDE MARKT 13 ; 3000 Leuven ; Belgique
• Région: Vlaams Gewest › Prov. Vlaams-Brabant › Arr. Leuven
• Type d’activité: Établissements d’enseignement supérieur ou secondaire
• Coût total: Aucune donnée